Immunogenicity: Risk Assessment in Drug Candidate Selection

Discover our latest whitepaper exploring how Abzena’s phase-appropriate immunogenicity testing strategy can help you identify and mitigate risks that can reduce a drug’s efficacy and cause adverse effects.

By integrating screening methods like in silico prediction with in vitro/ex vivo assays, we provide a clear path toward safer, more effective therapeutics.

Biologic drugs can be perceived as foreign if their amino acid sequence, structure, or post-translational modifications differ from the body’s proteins, potentially triggering anti-drug antibody (ADA) formation that neutralize the drug and can cause potential adverse side effects. Our white paper explains how combining Abzena’s iTope-AI platform for predictive T cell epitope analysis with our enhanced EpiScreen® 2.0 immunogenicity testing platform offers a robust means of pinpointing “hotspots,” evaluating immune responses in donor PBMCs, and refining candidates before they reach the clinic.

You’ll also learn how MHC Class II Associated Peptide Proteomics (MAPPs) delivers deeper insights into the specific peptides actually presented by dendritic cells, allowing targeted de-immunization without compromising therapeutic function. By adopting a proactive testing approach, you can address challenges posed by HLA diversity, protein aggregation, and glycosylation patterns while streamlining development timelines and reducing the chance of late-stage failures.

Access a copy of our whitepaper to discover how Abzena’s integrated immunogenicity solutions enable better lead selection, improved safety profiles, and a stronger likelihood of clinical success.